Skip to main content
    C

    Coya Therapeutics, Inc. Common Stock (COYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.34
    +0.16 (+3.83%)

    Market Cap: $98.05M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(9/14)
    Avg Surprise
    -6.57%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.37 - $-0.33
    3 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.39+9.4%
    60d ago$-0.39+9.4%
    30d ago$-0.350.0%
    7d ago$-0.350.0%
    Current$-0.35
    Revenue Consensus
    $78570
    Range$0 - $300000
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.26
    Range$-0.31 - $-0.19
    3 analysts
    Revenue Consensus
    $764030
    Range$45470 - $3M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.26---
    Sep 26EST
    		-$-0.35---
    Jun 26
    Reported Aug 11
    		$-0.28$-0.36+22.22%Beat+22.2%
    Mar 26
    Reported May 12
    		$-0.32N/A+53.87%Beat+27.7%
    Dec 25
    Reported Mar 16
    		$-0.34$-0.30-13.33%Miss-88.9%
    Sep 25
    Reported Nov 12
    		$-0.13N/A+56.67%Beat+50.0%
    Jun 25
    Reported Aug 12
    		$-0.36$-0.43+16.28%Beat-89.5%
    Mar 25
    Reported May 13
    		$-0.44$-0.12-266.67%Miss-25.7%
    Dec 24
    Reported Mar 18
    		$-0.18N/A+55.00%Beat-220.0%
    Sep 24
    Reported Nov 6
    		$-0.26$-0.41+36.59%Beat+23.5%
    Jun 24
    Reported Aug 12
    		$-0.19$-0.14-35.71%Miss+38.7%
    Mar 24
    Reported May 9
    		$-0.35$-0.29-20.69%Miss-25.0%
    Dec 23
    Reported Mar 19
    		$0.15$0.26-42.31%Miss+148.0%
    Sep 23
    Reported Nov 8
    		$-0.34$-0.37+8.11%Beat-70.0%
    Jun 23
    Reported Aug 8
    		$-0.31$-0.32+3.13%Beat-
    Mar 23
    Reported May 10
    		$-0.28$-0.43+34.88%Beat-
    Dec 22
    Reported Mar 29
    		$-0.31N/AN/ABeat-
    Sep 22
    Reported Dec 30
    		$-0.20$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.06EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-270.20%Operating Margin-2890.00%
    ROE-60.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio13.40xQuick Ratio13.40x
    Trading Statistics
    Beta0.58Avg Volume158.65K
    52-Week High$7.5552-Week Low$3.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.72
    SMA 20$4.87
    SMA 50$4.77
    SMA 200$4.70
    EMA 10$4.64
    EMA 20$4.73
    EMA 50$4.76
    EMA 200$4.89

    MACD

    Line: -0.08Signal: 0.00Hist: -0.08

    ADX

    ADX: 18.6+DI: 11.4-DI: 24.0

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$5.16

    Bollinger Bands

    Upper Band$5.41
    Lower Band$4.33
    %B Position2215%(Upper)
    Band Width0.01

    RSI (14-Day)

    Neutral
    38.7

    Momentum Oscillators

    Stoch %K7.7
    Stoch %D11.8
    Williams %R-81.8
    ROC (10d)-8.2%
    Momentum-0.39
    CCI (20d)-237.9
    MFI (14d)54.5

    Volatility Measures

    ATR (14d)$0.29(6.6%)
    StdDev (20d)0.27
    Hist Vol57.6%(High)

    Volume Flow

    VWAP$4.33
    OBV-3.7M
    AD Line-5.3M
    CMF (20d)-0.105

    Volume Metrics

    Avg Vol (20d)157.0K
    Vol Ratio1.5x(High)
    VWMA (20d)$4.84

    Pivot Points

    R3$4.98
    R2$4.81
    R1$4.50
    Pivot Point$4.33
    S1$4.01
    S2$3.84
    S3$3.53

    Advanced Oscillators

    TSI-8.25
    Ultimate Osc34.9
    KST1.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$243,745$251,147$3.96M$3.56M$163,616$257,884$1,952$0$3.43M$126,838$6.00M$0
    Cost of Revenue$0$0$-5,200,395$0$0$0$1.94M$0$0$0$1.61M$0
    Gross Profit$243,745$251,147$3.96M$3.56M$163,616$257,884$1,952$0$3.43M$126,838$6.00M$0
    Operating Expenses$7.29M$7.89M$9.99M$6.00M$6.58M$7.93M$4.08M$4.45M$6.66M$5.61M$4.19M$3.56M
    R&D$5.03M$4.11M$6.71M$3.43M$3.66M$5.21M$1.94M$2.22M$4.57M$3.16M$1.80M$1.59M
    SG&A$2.26M$3.78M$3.27M$2.56M$2.91M$2.71M$2.14M$2.22M$2.09M$2.44M$2.38M$1.96M
    Operating Income$-7,046,988$-7,640,217$-6,030,888$-2,432,897$-6,414,518$-7,676,922$-4,080,295$-4,450,289$-3,236,125$-5,483,002$1.82M$-3,564,063
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$1.79M$0$0$0$3.58M$0$0$0$0$0
    Income Before Tax$-6,638,260$-7,206,990$-7,821,284$0$-6,094,977$-7,306,757$-7,657,481$0$-2,891,680$-5,051,913$2.29M$-3,564,063
    Income Tax Expense$0$0$3,089$0$0$0$-720,287$0$0$0$0$0
    Net Income$-6,638,260$-7,206,990$-5,708,542$-2,115,831$-6,094,977$-7,306,757$-2,915,776$-4,021,418$-2,891,680$-5,051,913$1.27M$-3,421,974
    EBITDA$-6,635,453$-7,204,183$-5,698,612$-2,108,991$-6,088,137$-7,299,917$-3,629,223$-4,014,577$-2,884,840$-5,045,073$2.30M$-3,557,222
    EBIT$-6,638,260$-7,206,990$-5,705,453$-2,115,831$-6,094,977$-7,306,757$-3,636,063$-4,021,418$-2,891,680$-5,051,913$2.29M$-3,564,063
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about COYA

    News

    Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

    Coya Therapeutics announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS Trial for COYA 302 in ALS...

    BioSpace•10/14/26•Bullish

    ALS development takes priority as Coya Therapeutics (COYA) delays another trial's planned start.

    Coya Therapeutics is prioritizing its resources towards the ongoing development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS)...

    Stock Titan•10/14/26•Somewhat-Bearish

    Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

    Coya Therapeutics, Inc. (NASDAQ: COYA) announced its participation in Chardan's 10th Annual Healthcare Conference on October 20 in New York. Fred Grossman, DO, President & Chief Medical Officer...

    BioSpace•10/13/26•Somewhat-Bullish

    A New York panel will discuss Alzheimer's and Parkinson's on Oct. 20

    Coya Therapeutics (COYA) announced its participation in Chardan's 10th Annual Healthcare Conference on October 20th in New York. Fred Grossman, DO, President & Chief Medical Officer of Coya Therapeutics...

    Stock Titan•10/13/26•Bullish

    Coya Therapeutics Inc (COYA-Q) Stock Price and News

    This article provides comprehensive information on Coya Therapeutics Inc. (COYA-Q), a clinical-stage biotechnology company focused on developing treatments for systemic inflammation and neuroinflammation. It includes...

    The Globe and Mail•10/10/26•Somewhat-Bullish

    COYA Valuation and Fair Value

    P/E
    -4.1x
    P/B
    2.4x
    See GNG's fair value

    COYA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -2890.0%
    Net margin
    -270.2%
    ROE
    -60.5%
    FCF margin
    -196.1%

    COYA Competitors

    CompanyTicker
    PolyPidPYPD
    ImmuCell CorporationICCC
    The Joint CorpJYNT
    Milestone Pharmaceuticals IncMIST
    Humacyte IncHUMA
    Rani Therapeutics Holdings IncRANI
    Corbus Pharmaceuticals HoldingCRBP
    Pmv Pharmaceuticals IncPMVP

    Sector: Healthcare

    COYA Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    COYA Bull Case vs Bear Case

    Bull case

    • COYA beat EPS estimates in 75.0% of its last 8 reported quarters.
    • COYA grew quarterly revenue 49.0% year over year.
    • 100.0% of COYA's analyst ratings are Buy or Strong Buy.

    Bear case

    • COYA has a -270.2% net profit margin.

    COYA Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    -4.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.35
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About COYA

    Does COYA pay dividends?

    Coya Therapeutics, Inc. Common Stock (COYA) does not currently pay a regular dividend.

    What is COYA's market cap?

    Coya Therapeutics, Inc. Common Stock (COYA) has a market capitalization of $98.05M with a current stock price of $4.34.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In